無料セミナー : 2018年11月27日『オンコロジーにおける遺伝子治療・CAR-T細胞療法』 DelveInsight Business Research LLP共同開催
Atopic Dermatitis (AD) - Market Insight, Epidemiology and Market Forecast - 2027
|発行||DelveInsight Business Research LLP||商品コード||565327|
|出版日||ページ情報||英文 100 Pages
|アトピー性皮膚炎 (AD)：市場考察、疫学、市場予測 Atopic Dermatitis (AD) - Market Insight, Epidemiology and Market Forecast - 2027|
|出版日: 2018年03月01日||ページ情報: 英文 100 Pages||
当レポートでは、世界のアトピー性皮膚炎 (AD) の市場について分析し、疾患の概要や現在の治療手法／アルゴリズム、新たな治療薬の開発・上市の動き、主要製品の概要、世界全体および主要国 (米国・欧州諸国・日本) の市場動向 (今後11年間分)、主な市場促進・抑制要因、現在のアンメットニーズ、潜在的な市場機会などについて調査しております。
DelveInsight's 'Atopic Dermatitis - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Atopic Dermatitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Atopic Dermatitis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2016-2027
The DelveInsight Atopic Dermatitis market report gives the thorough understanding of the Atopic Dermatitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Atopic Dermatitis in the US, Europe, and Japan.
The Atopic Dermatitis (AD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The disease epidemiology covered in the report is segmented by prevalent population of Atopic Dermatitis, Severity [Children & Adults], Pruritus burden, Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults] in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the prevalent population of Atopic Dermatitis was estimated to be 40.78 Million [7MM] in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States accounts for the highest AD Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Adults are largely affected with the atopic dermatitis Among EU5, France has been reported to have the highest prevalent population of atopic dermatitis.
This segment of the Atopic Dermatitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III & Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The drugs marketed for the treatment of Atopic Dermatitis mainly include Dupixent (dupilumab), Eucrisa (crisaborole), Desonate (desonide), Verdeso (desonide), Elidel (pimecrolimus), Protopic (tacrolimus), Allegra (Fexofenadine hydrochloride) and Neoral solution (cyclosporine).
Detailed chapters for all of these drugs, along with the upcoming therapies i.e., [Nemolizumab (Galderma Pharma), Tralokinumab (LEO Pharma), Tradipitant (Vanda Pharmaceuticals), ZPL-389 (Novartis), NST-141 (Nippon Shinyaku), etc., have been covered in the report.
The Atopic Dermatitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Atopic Dermatitis was estimated to be USD 2.2 billion in 2016, and is expected to increase at a CAGR of XX% from 2016-2027.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.